174 related articles for article (PubMed ID: 7046902)
1. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase.
Liebman HA; Wada JK; Patch MJ; McGehee W
Cancer; 1982 Aug; 50(3):451-6. PubMed ID: 7046902
[TBL] [Abstract][Full Text] [Related]
2. Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors.
Clarkson B; Krakoff I; Burchenal J; Karnofsky D; Golbey R; Dowling M; Oettgen H; Lipton A
Cancer; 1970 Feb; 25(2):279-305. PubMed ID: 4905154
[No Abstract] [Full Text] [Related]
3. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study.
Mazzucconi MG; Gugliotta L; Leone G; Dragoni F; Belmonte MM; De Stefano V; Chistolini A; Tura S; Mandelli F
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):23-8. PubMed ID: 7514043
[TBL] [Abstract][Full Text] [Related]
4. Hypercoagulability during L-asparaginase treatment: the effect of antithrombin III supplementation in vivo.
Gugliotta L; D'Angelo A; Mattioli Belmonte M; Viganò-D'Angelo S; Colombo G; Catani L; Gianni L; Lauria F; Tura S
Br J Haematol; 1990 Apr; 74(4):465-70. PubMed ID: 2189489
[TBL] [Abstract][Full Text] [Related]
5. Fatal pulmonary embolism and antithrombin III deficiency in adult lymphoblastic leukaemia during L-asparaginase therapy.
Barbui T; Rodeghiero F; Meli S; Dini E
Acta Haematol; 1983; 69(3):188-91. PubMed ID: 6404103
[TBL] [Abstract][Full Text] [Related]
6. Greater decrease of fibrinogen as compared to antithrombin III in L-asparaginase treated leukemia patients.
Vicarioto M; Rosolen A; Cappellato MG; Zanesco L; Girolami A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(5):663-9. PubMed ID: 2435632
[TBL] [Abstract][Full Text] [Related]
7. Some clinical observations on the treatment with L-asparaginase of the acute leukemias.
Marmont AM; Damasio EE
Recent Results Cancer Res; 1970; 33():296-315. PubMed ID: 4949165
[No Abstract] [Full Text] [Related]
8. [Preliminary results of the clinical study of a Soviet--produced L-asparaginase from E. coli].
Kondrat'eva NA; Lorie IlI ; Kruglova GV; Vorob'ev AI; Koshel' IV
Antibiotiki; 1977 Sep; 22(9):852-7. PubMed ID: 334060
[No Abstract] [Full Text] [Related]
9. Clinical experience with L-asparaginase.
Carbone PP; Haskell CM; Leventhal BG; Block JB; Selawry OS
Recent Results Cancer Res; 1970; 33():236-43. PubMed ID: 4949163
[No Abstract] [Full Text] [Related]
10. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease.
Haskell CM; Canellos GP; Leventhal BG; Carbone PP; Block JB; Serpick AA; Selawry OS
N Engl J Med; 1969 Nov; 281(19):1028-34. PubMed ID: 4898857
[No Abstract] [Full Text] [Related]
11. [First results of the treatment of acute leukemia with L-asparaginase].
Marmont A; Damasio E; Bordo D; Fazio F; Gori E; Rossi F
Haematologica; 1970; 55(9):593-6. PubMed ID: 4996527
[No Abstract] [Full Text] [Related]
12. A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase.
Mattioli Belmonte M; Gugliotta L; Delvos U; Catani L; Vianelli N; Cascione ML; Belardinelli AR; Mottola L; Tura S
Haematologica; 1991; 76(3):209-14. PubMed ID: 1743591
[TBL] [Abstract][Full Text] [Related]
13. L-asparaginase in acute lymphoblastic leukemia treatment: the role of human antithrombin III concentrates in regulating the prothrombotic state induced by therapy.
Pogliani EM; Parma M; Baragetti I; Mostarda G; Rivolta F; Maffé P; Corneo G
Acta Haematol; 1995; 93(1):5-8. PubMed ID: 7725851
[TBL] [Abstract][Full Text] [Related]
14. Antithrombin III during high-dose cytosine arabinoside therapy with or without asparaginase.
Marra R; Pagano L; De Stefano V; Leone G; Bizzi B
Acta Haematol; 1986; 75(2):96-9. PubMed ID: 3090830
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of leukemia in USA. 2. L asparaginase in leukemia].
Böttiger LE
Lakartidningen; 1969 Jan; 66(5):455-60. PubMed ID: 5254602
[No Abstract] [Full Text] [Related]
16. Asparaginase in acute leukaemia.
Colebatch JH; Matthews RN; Gordon PM; Tan CL; Santamaria JN; Lay HN
Med J Aust; 1970 Feb; 1(6):282. PubMed ID: 5266297
[No Abstract] [Full Text] [Related]
17. Reduced antithrombin III levels during L-asparaginase therapy.
Buchanan GR; Holtkamp CA
Med Pediatr Oncol; 1980; 8(1):7-14. PubMed ID: 6934369
[TBL] [Abstract][Full Text] [Related]
18. A summary of the clinical status of asparaginase.
Burchenal JH
Recent Results Cancer Res; 1970; 33():350-4. PubMed ID: 5292724
[No Abstract] [Full Text] [Related]
19. L-asparaginase--clinical experience in leukaemia, lymphoma and carcinoma.
Biggs JC; Chesterman CN; Holliday J
Aust N Z J Med; 1971 Feb; 1(1):1-7. PubMed ID: 4934741
[No Abstract] [Full Text] [Related]
20. Cerebral thrombotic complications in adolescent leukemia/lymphoma patients treated with L-asparaginase-containing chemotherapy.
Imamura T; Morimoto A; Kato R; Izumi M; Murakami A; Matuo S; Kiyosawa N; Kano G; Yoshioka H; Sugimoto T; Imashuku S
Leuk Lymphoma; 2005 May; 46(5):729-35. PubMed ID: 16019511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
